That sentence as quoted seems to suggest that Brilacidin targets bacteria vs. non-bacteria, not that it targets certain types of bacteria-in which case it could have said something like "selectively targets gram positive bacteria" or other specific limitations.
As of now, Brilacidin seems to be under testing for both possible antiviral function as well as probably being looked at for more peripheral effects such as suppression of inflammation, bacterial pneumonia, etc. Any possible progression to actual vaccine use would be a godsend to both investors and those with the illness but such would probably be quite a ways off yet. I'll be more than happy if it proves effective in the supporting role.